All In Biotech

Drug Trial Radar · NCT04563195

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Feb 1, 2022

Primary completion

Dec 2023

Study completion Jan 2025

Sponsor

Lead sponsor
Matthew C. BakerAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.

Conditions

  • Primary Sjogren's Syndrome

Interventions

  • tibulizumab (LY3090106)Drug

    subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. whole unstimulated sialometryTime frame: baseline
  2. whole unstimulated sialometryTime frame: week 12
  3. salivary gland ultrasoundTime frame: baseline
  4. salivary gland ultrasoundTime frame: week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.